NEW YORK, NY / ACCESSWIRE / December 1, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
FAF Shareholders Click Here: https://www.zlk.com/pslra-1/first-american-financial-corp-loss-submission-form?prid=11289&wire=1
ZSAN Shareholders Click Here: https://www.zlk.com/pslra-1/zosano-pharma-corporation-loss-submission-form?prid=11289&wire=1
TILE Shareholders Click Here: https://www.zlk.com/pslra-1/interface-inc-loss-submission-form?prid=11289&wire=1
* ADDITIONAL INFORMATION BELOW *
First American Financial Corp. (NYSE:FAF)
FAF Lawsuit on behalf of: investors who purchased February 17, 2017 - October 22, 2020
Lead Plaintiff Deadline : December 24, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/first-american-financial-corp-loss-submission-form?prid=11289&wire=1
According to the filed complaint, during the class period, First American Financial Corp. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company failed to implement basic security standards to protect its customers' sensitive personal information and data; (2) the Company faced a heightened risk of cybersecurity failure due to its automation and efficiency initiatives; and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times.
Zosano Pharma Corporation (NASDAQ:ZSAN)
ZSAN Lawsuit on behalf of: investors who purchased February 13, 2017 - September 30, 2020
Lead Plaintiff Deadline : December 28, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/zosano-pharma-corporation-loss-submission-form?prid=11289&wire=1
According to the filed complaint, during the class period, Zosano Pharma Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's clinical results reflected differences in zolmitriptan exposures observed between subjects receiving different lots; (2) pharmocokinetic studies submitted in connection with the Company's New Drug Application included patients exhibiting unexpected high plasma concentrations of zolmitriptan; (3) as a result of the foregoing differences among patient results, the U.S. Food and Drug Administration was reasonably likely to require further studies to support regulatory approval of the Company's lead product candidate, Qtrypta; (4) as a result, regulatory approval of Qtrypta was reasonably likely to be delayed; and (5) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.
Interface, Inc. (NASDAQ:TILE)
TILE Lawsuit on behalf of: investors who purchased March 2, 2018 - September 28, 2020
Lead Plaintiff Deadline : January 11, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/interface-inc-loss-submission-form?prid=11289&wire=1
According to the filed complaint, during the class period, Interface, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Interface had inadequate disclosure controls and procedures and internal control over financial reporting; (ii) consequently, Interface, inter alia, reported artificially inflated income and earnings per share ("EPS") in 2015 and 2016; (iii) Interface and certain of its employees were under investigation by the SEC with respect to the foregoing issues since at least as early as November 2017, had impeded the SEC's investigation, and downplayed the true scope of the Company's wrongdoing and liability with respect to the SEC investigation; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP